Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Analysis of safety and efficacy in patients with renal impairment

Clinical Lung Cancer

Volumn 16, Issue 2, 2015, Pages 112-120

  Langer, Corey J ^a   Hirsh, Vera ^b   Ko, Amy ^c   Renschler, Markus F ^c   Socinski, Mark A ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Creatinine clearance; Renal function; Taxanes

Indexed keywords

CARBOPLATIN; CREATININE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; KIDNEY FAILURE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RENAL INSUFFICIENCY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923079735     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.09.003     Document Type: Article

References (30)

1. R.D. Lindeman Changes in renal function with aging. Implications for treatment Drugs Aging 2 1992 423 431
2. C.J. Girman, T.D. Kou, and K. Brodovicz Risk of acute renal failure in patients with type 2 diabetes mellitus Diabet Med 29 2012 614 621
3. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Draft guidance for industry. Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Accessed September 19, 2014.
4. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for industry. Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. 1998. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf. Accessed September 19, 2014.
5. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review (CSR), 1975-2010. Available at: http://seer.cancer.gov/csr/1975-2010/. Accessed September 19, 2014.
6. G. Ohara, K. Kurishima, and K. Nakazawa Age-dependent decline in renal function in patients with lung cancer Oncol Lett 4 2012 38 42
7. I. Arany, and R.L. Safirstein Cisplatin nephrotoxicity Semin Nephrol 23 2003 460 464
8. US Food and Drug Administration. Carboplatin dosing. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm228974.htm. Accessed September 19, 2014.
9. Alimta (pemetrexed) [prescribing information] 2013 Eli Lilly and Company East Hanover, NJ
10. Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [prescribing information] 2013 Celgene Corporation Summit, NJ
11. E.R. Gardner, W.L. Dahut, and C.D. Scripture Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel Clin Cancer Res 14 2008 4200 4205
12. N. Desai, V. Trieu, and Z. Yao Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel Clin Cancer Res 12 2006 1317 1324
13. A. Sparreboom, C.D. Scripture, and V. Trieu Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (taxol) Clin Cancer Res 11 2005 4136 4143
14. N. Chen, Y. Li, Y. Ye, M. Palmisano, R. Chopra, and S. Zhou Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel J Clin Pharmacol 54 2014 1097 1107
15. I. Okamoto, N. Yamamoto, and K. Kubota Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer Invest New Drugs 30 2012 1132 1137
16. C.P. Belani, C.M. Kearns, and E.G. Zuhowski Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer J Clin Oncol 17 1999 676 684
17. M.A. Socinski, I. Bondarenko, and N.A. Karaseva Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial J Clin Oncol 30 2012 2055 2062
18. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
19. Cisplatin [prescribing information] 2012 Teva Pharmaceuticals USA Sellersville, PA
20. L. Chu, M. Ulcickas Yood, and M. Loghman-Adham Renal impairment after chemotherapy in lung (LC), colorectal (CRC), and breast cancer (BC) patients (pts) from the Henry Ford Health System (HFHS) tumor registry J Clin Oncol 30 2012 abstract 1590
21. B. Kutluk Cenik, H. Sun, and D.E. Gerber Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer Lung Cancer 80 2013 326 332
22. K. Tipton Patel, M.B. Pace, M.J. Rivera, A. Siddiqui, and E.S. Kim Safety and efficacy of pemetrexed in lung cancer patients with renal insufficiency J Thorac Oncol 7 suppl 4 2012 abstract S242
23. A.C. Mita, C.J. Sweeney, and S.D. Baker Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function J Clin Oncol 24 2006 552 562
24. R.D. Lindeman Assessment of renal function in the old. Special considerations Clin Lab Med 13 1993 269 277
25. M.A. Socinski, C.J. Langer, and I. Okamoto Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer Ann Oncol 24 2013 314 321
26. T. Hahn, S. Yao, and L.M. Dunford A comparison of measured creatinine clearance versus calculated glomerular filtration rate for assessment of renal function before autologous and allogeneic BMT Biol Blood Marrow Transplant 15 2009 574 579
27. E.J. Park, K. Wu, and Z. Mi A systematic comparison of Cockcroft-Gault and Modification of Diet in Renal Disease equations for classification of kidney dysfunction and dosage adjustment Ann Pharmacother 46 2012 1174 1187
28. A.G. Bostom, F. Kronenberg, and E. Ritz Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels J Am Soc Nephrol 13 2002 2140 2144
29. C. Melloni, E.D. Peterson, and A.Y. Chen Cockcroft-Gault versus Modification of Diet in Renal Disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes J Am Coll Cardiol 51 2008 991 996
30. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Available at: http://www2.kidney.org/professionals/KDOQI/guidelines-ckd/toc.htm. Accessed September 19, 2014.